FasL interacts with CD95 (also known as Fas or APO-1), activating a caspase cascade that lead to apoptosis in cancer cells (51).TRAIL interacts with death receptors DR4, DR5, decoy receptor 1 (DcR1), and DcR2 (52). Here, FAS is linked to cancer.